國家衛生研究院 NHRI:Item 3990099045/11510
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 911216      Online Users : 926
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11510


    Title: CCM111 prevents hepatic fibrosis via cooperative inhibition of TGF-Beta Wnt and STAT3 signaling pathways
    Other Titles: CCM111 prevents hepatic fibrosis via cooperative inhibition of TGF-β Wnt and STAT3 signaling pathways
    Authors: Lin, IY;Chiou, YS;Wu, LC;Tsai, CY;Chen, CT;Chuang, WC;Lee, MC;Lin, CC;Lin, TT;Chen, SC;Pan, MH;Ma, N
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: CCM111 is an aqueous extract of Antrodia cinnamomea (AC) that has exhibited anti-liver fibrosis functions. However, the detailed mechanisms of AC action against liver fibrosis have not been elucidated yet. The present research showed that CCM111 significantly lowered the levels of the hepatic enzyme markers glutamate oxaloacetate transaminase (GOT) and glutamic pyruvic transaminase (GPT), prevented liver damage and collagen deposition, and downregulated TGF-β/Smad signaling in a dose-dependent manner compared with CCl4 treatment alone. CCM111 markedly inhibited TGF-β Wnt and STAT3 signaling pathway-regulated downstream genes in the liver by next-generation sequencing. The antifibrotic mechanisms of CCM111 were further demonstrated in HSC-T6 cells. Our data demonstrated for the first time that CCM111 can protect against CCl4-induced liver fibrosis by the cooperative inhibition of TGF-β-, Wnt- and STAT3-dependent proinflammatory and profibrotic mediators, suggesting that CCM111 might be a candidate for preventing and treating chronic fibrotic liver diseases.
    Date: 2019-01
    Relation: Journal of Food and Drug Analysis. 2019 Jan;27(1):184-194.
    Link to: http://dx.doi.org/10.1016/j.jfda.2018.09.008
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1021-9498&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000455651700017
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85055741136
    Appears in Collections:[Chiung-Tong Chen] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    SCP85055741136.pdf2411KbAdobe PDF282View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback